Lindbrook Capital, LLC Akero Therapeutics, Inc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 1,559 shares of AKRO stock, worth $43,589. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,559
Previous 1,539
1.3%
Holding current value
$43,589
Previous $36,000
22.22%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$221 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$198 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$166 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$156 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$146 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.3B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...